- Home
- IBIO vs NLSP Comparison
IBIO vs NLSP Comparison
Compare IBIO & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBIO
- NLSP
- Stock Information
- Founded
- IBIO 2008
- NLSP 2015
- Country
- IBIO United States
- NLSP Switzerland
- Employees
- IBIO N/A
- NLSP N/A
- Industry
- IBIO Biotechnology: Pharmaceutical Preparations
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- IBIO Health Care
- NLSP Health Care
- Exchange
- IBIO Nasdaq
- NLSP Nasdaq
- Market Cap
- IBIO 11.9M
- NLSP 12.4M
- IPO Year
- IBIO N/A
- NLSP 2021
- Fundamental
- Price
- IBIO $0.66
- NLSP $1.80
- Analyst Decision
- IBIO Strong Buy
- NLSP
- Analyst Count
- IBIO 2
- NLSP 0
- Target Price
- IBIO $5.50
- NLSP N/A
- AVG Volume (30 Days)
- IBIO 538.2K
- NLSP 170.0K
- Earning Date
- IBIO 09-19-2025
- NLSP 08-12-2025
- Dividend Yield
- IBIO N/A
- NLSP N/A
- EPS Growth
- IBIO N/A
- NLSP N/A
- EPS
- IBIO N/A
- NLSP N/A
- Revenue
- IBIO $375,000.00
- NLSP N/A
- Revenue This Year
- IBIO $81.33
- NLSP N/A
- Revenue Next Year
- IBIO N/A
- NLSP N/A
- P/E Ratio
- IBIO N/A
- NLSP N/A
- Revenue Growth
- IBIO 650.00
- NLSP N/A
- 52 Week Low
- IBIO $0.64
- NLSP $1.30
- 52 Week High
- IBIO $6.89
- NLSP $9.11
- Technical
- Relative Strength Index (RSI)
- IBIO 33.40
- NLSP 34.22
- Support Level
- IBIO $0.71
- NLSP $1.91
- Resistance Level
- IBIO $0.78
- NLSP $2.11
- Average True Range (ATR)
- IBIO 0.03
- NLSP 0.14
- MACD
- IBIO -0.00
- NLSP -0.05
- Stochastic Oscillator
- IBIO 6.43
- NLSP 14.06
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.